Schmitt F C, Soares R, Cirnes L, Seruca R
Institute of Molecular Pathology and Immunology, IPATIMUP, Porto Medical School, Portugal.
Pathol Res Pract. 1998;194(12):815-9. doi: 10.1016/s0344-0338(98)80083-6.
The aim of this study was to evaluate the concordance between the presence of p53 mutations in breast carcinomas expressing the protein by immunohistochemistry. A series of 60 breast carcinomas was evaluated by immunohistochemistry using monoclonal antibodies against p53 protein (DO 7 and PAb 1801). Twenty cases classified as being positive for p53 according to the current approach (if 5% or more of neoplastic cells contained reaction product in the nucleus) were used for molecular studies. These cases were re-assessed semi-quantitatively using a scoring system based on intensity and percentage of stained cells. DNA was phenol-chloroform extracted from microdissected normal and tumour cells obtained from formalin-fixed, paraffin-embedded tissue sections. Mutations in the p53 gene were analysed by SSCP (single strand conformational polymorphism) with primers covering exons 2-3 to 11. Ten out of the 20 p53-positive cases presented mutations detected by SSCP analysis. Mutations have been found in several exons ranging from exon 4 to exon 10. We observed a positive relationship between the presence of mutations and immunohistochemical evaluation of p53 protein expression using a semiquantitative scoring system. All cases with more than 2/3 stained tumour cells and strong intensity of staining exhibited p53 mutations. At variance, no p53 mutations were found in cases with less than 1/3 stained tumour cells and moderate intensity of staining. Therefore, only the identification of positivity for p53 detected by immunohistochemistry did not always reflect the detection of p53 mutations in breast cancer, however the use of a semi-quantitative approach seems to be useful as an indicator of the presence of mutation.
本研究的目的是评估通过免疫组织化学检测表达该蛋白的乳腺癌中p53突变的一致性。使用针对p53蛋白的单克隆抗体(DO 7和PAb 1801)通过免疫组织化学对一系列60例乳腺癌进行评估。根据当前方法分类为p53阳性的20例病例(如果5%或更多的肿瘤细胞在细胞核中含有反应产物)用于分子研究。使用基于染色细胞强度和百分比的评分系统对这些病例进行半定量重新评估。从福尔马林固定、石蜡包埋组织切片中获得的显微切割正常细胞和肿瘤细胞中提取酚-氯仿DNA。用覆盖外显子2-3至11的引物通过单链构象多态性(SSCP)分析p53基因中的突变。在20例p53阳性病例中,有10例通过SSCP分析检测到突变。在从外显子4到外显子10的几个外显子中发现了突变。我们观察到使用半定量评分系统时,突变的存在与p53蛋白表达的免疫组织化学评估之间存在正相关。所有肿瘤细胞染色超过2/3且染色强度强的病例均表现出pS3突变。相比之下,肿瘤细胞染色少于1/3且染色强度中等的病例未发现p53突变。因此,仅通过免疫组织化学检测到的p53阳性并不总是反映乳腺癌中p53突变的检测,然而使用半定量方法似乎有助于作为突变存在的指标。